Edgewise Therapeutics posted a GAAP net loss of $57.33 million, or $0.53 per share, for Q2 2026.
R&D expense climbed to $47.55 million from $33.56 million a year earlier, driven by higher clinical development activity and personnel costs.
G&A expense rose to $14.4 million from $9.05 million on higher personnel-related costs and increased professional fees.
Cash, cash equivalents and marketable securities totaled $460.71 million at June 30, excluding $1.55 billion upfront proceeds from the sevasemten sale.
Edgewise completed the Servier deal in July for $1.55 billion upfront, up to $2.65 billion total; it targets a Q4 2026 Phase 3 start for EDG-7500.
EWTX•
